Abstract
In oncology, the use of standardized criteria to assess tumor response is crucial in clinical trials and routine care. Before 1999, criteria for malignant lymphomas were highly variable, complicating comparisons and assessment of treatment efficacy. This need for standardization to improve the reliability of results, particularly regarding normal lymph node size and how response is measured and assessed, led to the development of the Response Evaluation Criteria in Solid Tumors (RECIST) and Cheson criteria for lymphomas. The recent Response Evaluation Criteria in Lymphoma (RECIL), were specifically developed for the assessment of response to treatment in lymphomas, but these criteria are imperfect and the trend is to use the Lugano criteria instead.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
